Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RenascienceTSE:4889 -2.25%53 Quick Ratio is 19.40 as of Mar. 2026, which is 14% below its 10-year median of 22.64. GuruFocus rates TSE:4889 with a GF Score™ of 53/100 and a GF Value™ of 円331.42 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Renascience ranks better than 98.13% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Renascience's quick ratio for the quarter that ended in Mar. 2026 was 19.40.
Renascience has a quick ratio of 19.40. It generally indicates good short-term financial strength.
The historical rank and industry rank for Renascience's Quick Ratio or its related term are showing as below:
TSE:4889'
s Quick Ratio Range Over the Past 10 Years
Min: 12.38 Med: 22.64 Max: 89.31
Current: 19.4
During the past 7 years, Renascience's highest Quick Ratio was 89.31. The lowest was 12.38. And the median was 22.64.
TSE:4889's Quick Ratio is ranked better than 98.13% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 1.89
vs TSE:4889: 19.40
Renascience (TSE:4889) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Renascience Quick Ratio Related Terms
Renascience Quick Ratio Historical Data
* Premium members only.
The historical data trend for Renascience's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Renascience's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renascience Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Renascience's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Renascience's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Renascience's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renascience (TSE:4889) has a Quick Ratio of 19.40 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Renascience and its competitors. This is 14% below median its historical median of 22.64. Over the past decade, Renascience's Quick Ratio has ranged from 12.38 to 89.31. According to the industry distribution chart, Renascience ranks #16 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 1.9%.
Is Renascience's Quick Ratio too high?
Renascience's current Quick Ratio of 19.40 is 14% below median its 10-year median of 22.64. Over the past 10 years, this metric has ranged from a low of 12.38 to a high of 89.31. The Medical Devices & Instruments industry median Quick Ratio is 1.89. Renascience's value of 19.40 is 926.5% above this industry median. Based on the distribution chart, Renascience ranks #16 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Renascience has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Renascience's Quick Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Renascience ranks #16 out of 854 companies for Quick Ratio. This places Renascience in the top 2% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.89. Renascience's value of 19.40 is 926.5% above this benchmark. Historically, Renascience's own Quick Ratio has ranged from 12.38 to 89.31 over the past decade. While the company's 10-year median is 22.64 vs. the industry median of 1.89, Renascience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.89, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Renascience's current Quick Ratio of 19.40 is 926.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Renascience and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renascience's current Quick Ratio is 19.40, which is 14% below median its own 10-year median of 22.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renascience stock overvalued right now?
Based on GuruFocus' analysis, Renascience (TSE:4889) is currently considered Significantly Overvalued. The stock's GF Value™ is 円331.42, compared to a current price of 円1,522.00 — trading 359.2% above its estimated fair value. The current Quick Ratio is 19.40, which is 14% below median its 10-year median of 22.64 and 926.5% above the Medical Devices & Instruments industry median of 1.89. Renascience's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Renascience (TSE:4889), the current Quick Ratio is 19.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Renascience (TSE:4889) Overvalued in 2026?
Based on GuruFocus' analysis, Renascience stock appears to be overvalued.
The current stock price of 円1,522.00 is trading 359.2% above its estimated GF Value™ of 円331.42.
GuruFocus considers Renascience to be Significantly Overvalued.
Key valuation signals for TSE:4889:
Quick Ratio: 19.40 (14% below median its 10-year median of 22.64)
GF Value™: 円331.42 vs. price of 円1,522.00 (359.2% above fair value)
Industry Position: 926.5% above the Medical Devices & Instruments median (#16 of 854)
No single metric tells the full story. See the TSE:4889 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Renascience Inc is engaged in the Development and commercialization of pharmaceuticals, medical devices, pieces of software as a medical device (SaMD) utilizing AI, etc.
53GF Score
Get the complete analysis for TSE:4889
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4889 has been successfully added to your 
